โน๏ธ About
- A very common cause of anaemia, especially in advanced CKD (stages 3โ5).
- Caused mainly by reduced renal erythropoietin (EPO) production โ reduced red cell synthesis.
- Contributes to fatigue, reduced exercise tolerance, left ventricular hypertrophy, and poorer quality of life.
๐งฌ Aetiology
- โฌ๏ธ EPO synthesis โ impaired bone marrow red cell production.
- Uraemia โ shortened red cell survival.
- Iron deficiency โ due to reduced absorption, chronic inflammation, and dialysis/GI blood loss.
- Folate deficiency โ may occur from dialysis-related losses.
๐ Investigations
- FBC: Normocytic, normochromic anaemia; โ Hb; reticulocytes low/normal.
- Blood film: Echinocytes (โburr cellsโ).
- U&E: Raised urea/creatinine.
- eGFR: Anaemia more likely if GFR < 30 ml/min/1.73 mยฒ.
- Iron studies: Ferritin and transferrin saturation (note: ferritin = acute-phase reactant).
- CRP/ESR: May indicate chronic inflammation.
Additional Tests (exclude other causes)
- Vitamin B12 and folate levels.
- Haemolysis screen: haptoglobin, LDH, bilirubin, DAT.
- Serum/urine protein electrophoresis ยฑ free light chains (exclude myeloma).
- Hb electrophoresis (exclude thalassaemia/haemoglobinopathy).
- Bone marrow biopsy if cytopenias unexplained.
๐ Management
- Correct reversible causes: Replace iron, folate, or B12 as needed.
โก๏ธ IV iron often preferred in dialysis patients.
- Erythropoiesis-stimulating agents (ESAs):
- Epoetin alfa/beta: 50โ100 units/kg IV/SC, 3ร weekly (often with dialysis).
- Darbepoetin alfa: Longer half-life โ weekly dosing.
- Peginesatide / Methoxy-PEG-Epoetin beta: Monthly dosing.
- Target Hb: 100โ120 g/L.
โ ๏ธ Avoid overcorrection (>130 g/L) โ โ stroke & thrombotic risk.
- Optimise CKD care: control BP, manage boneโmineral disease, ensure adequate dialysis.
References
Clinical Pearl:
Anaemia of CKD = typically normocytic + hypoproliferative.
Always exclude iron, folate, or B12 deficiency before ESAs.
Over-correcting Hb can worsen cardiovascular outcomes.